In type II DCs, DMF performed its therapeutic effect via inducing glutathione (GSH) depletion of DCs, followed by increasing the expression of antioxidant hemoxygenase-1 (HO-1) gene and impaired phosphorylation of STAT1 to ameliorate psoriasis and MS (Multiple Sclerosis) [76]. Here, HMOX1 is linked to psoriasis.